Lymphoma, breast cancer survivors have greater risk of CHF

Doctor and patient
Photo courtesy of CDC
Results of a retrospective study showed that survivors of lymphoma or breast cancer had a significantly greater risk of congestive heart failure (CHF) than patients who did not have cancer. This increased risk was observed as early as a year after cancer diagnosis but was still present 20 years after diagnosis. Overall, 1 in 10 cancer patients had CHF at the 20-year mark. [Read Article]

Pacritinib bests BAT, doesn’t seem to affect survival

Micrograph showing myelofibrosis
Final results from the PERSIST-2 trial suggest pacritinib can be more effective than best available therapy (BAT) for patients with myelofibrosis and thrombocytopenia, and the drug has no significant effect on survival. Patients who received pacritinib were more likely to experience at least a 35% reduction in spleen volume and a 50% reduction in total symptom score (TSS). In addition, there was no significant difference in survival between patients who received pacritinib and those who received BAT. [Read Article]

New mutation linked to familial erythrocytosis

Red blood cells
Researchers say they have discovered a mutation associated with hereditary erythrocytosis. The mutation causes a messenger RNA (mRNA) that is not normally involved in the formation of proteins to be reprogrammed so that it produces erythropoietin (EPO), thereby abnormally increasing red blood cell production. Radek Skoda, MD, of the University of Basel in Switzerland, and his colleagues described this discovery in NEJM. [Read Article]